Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

New Armenian Medical Journal (ISSN: 1829-0825, E-ISSN: 1829-0825) is a prominent academic publication established by Yerevan State Medical University, dedicated to advancing the field of medicine through high-quality research and scholarly discourse. Located in Armenia, this journal serves as a vital platform for disseminating innovative findings and clinical practices, with a particular focus on the regional healthcare landscape as well as global health issues. While currently categorized in the lower quartile (Q4) of general medicine, it demonstrates a commitment to improving its impact factor and ranking, evidenced by its ongoing publication from 2009 to 2024. The journal embraces a diverse scope that encompasses miscellaneous topics within medical research, catering to the needs of practitioners, researchers, and students alike. Though not an open-access journal, it offers valuable insights and knowledge that contribute meaningfully to the medical community. By participating in this scholarly dialogue, readers can enhance their understanding and foster advancements in the ever-evolving field of medicine.

Welcome to Advances in Clinical and Experimental Medicine, an esteemed publication by WROCLAW MEDICAL UNIVERSITY, dedicated to advancing the essential fields of clinical and experimental medicine. With an open access model since 2017, this journal ensures that researchers, healthcare professionals, and students worldwide can freely access high-quality scientific content. Covering a broad spectrum of topics including biochemistry, genetics, internal medicine, and pharmacology, Advances in Clinical and Experimental Medicine has established itself as a pivotal resource in the scientific community, currently holding prestigious rankings such as Q2 in Biochemistry, Genetics, and Molecular Biology (miscellaneous) and Q1 in Reviews and References (medical) for 2023. Spanning over two decades of rigorous research publication, the journal is a critical platform for sharing innovative findings and fostering collaboration among scholars, making it an invaluable asset for those at the forefront of medical science.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE is a prestigious journal published by SPRINGER, dedicated to advancing knowledge in the fields of biochemistry, genetics, molecular biology, and medicine. Established in 1956 and continuing to be relevant through to 2024, this journal provides a vital platform for researchers to publish original findings and significant reviews that contribute to these essential disciplines. With an ISSN of 0007-4888 and an E-ISSN of 1573-8221, it enjoys a respectable standing in the academic community, currently positioned in the Q3 quartile of both Biochemistry, Genetics and Molecular Biology, and Medicine categories for 2023. Despite its traditional subscription model, the journal reaches a wide audience of professionals, students, and researchers, who benefit from timely access to impactful research and experimental studies. By fostering a rich dialogue in experimental biology and medicine, this journal plays an important role in shaping ongoing research and understanding of complex biological systems.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Cukurova Medical Journal is a distinguished open-access publication specializing in the field of medicine, dedicated to advancing the exchange of knowledge and research findings since its inception in 2011. Published by Cukurova University, Faculty of Medicine, this journal features a diverse array of peer-reviewed articles that cater to a global readership of researchers, healthcare professionals, and students striving to stay informed about the latest developments in medical science. With its commitment to accessibility, Cukurova Medical Journal facilitates the dissemination of critical research without barriers, empowering scholars and practitioners to enhance their understanding and contribute to the field. While specific metrics such as HIndex and Scopus ranks are currently unavailable, the journal aims to achieve high academic standards and impact within the medical community. Based in Adana, Türkiye, the journal also embraces a rich cultural context, fostering innovative research and collaboration across borders.

Welcome to the JCPSP-Journal of the College of Physicians and Surgeons Pakistan, a pivotal platform for advancing knowledge in the field of medicine. Published by the College of Physicians and Surgeons Pakistan, this distinguished journal, with the ISSN 1022-386X and E-ISSN 1681-7168, has been disseminating critical research and clinical insights since 1996. With a focus on various realms of general medicine and holding a current Scopus rank of #291 out of 636, the JCPSP is classified in the Q3 quartile for miscellaneous medicine, indicating its growing influence and expertise. The journal aims to foster scholarly communication and collaboration among healthcare professionals, researchers, and students in Pakistan and beyond, enhancing clinical practice and medical education. Although it does not currently offer Open Access, its curated content and comprehensive research articles are essential for those engaged in the medical sciences. Join us in exploring the latest findings and contributions impacting the healthcare landscape in Pakistan and worldwide.

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.